Biodistribution of nonviral cationic vector/DNA complexes was studied after systemic or intratracheal administration to the lungs and correlated with transgene expression. Intravenous injection in ...

HAMPTON, England--(BUSINESS WIRE)--Touchlight, a CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA (dbDNA) technology, today announced that the Company has used its ...

Researchers found that PD-1-enhanced DNA vaccination can induce sustained virus-specific CD8+ T cell immunity in an AIDS monkey model. The vaccinated monkeys remained free of AIDS for six years and ...

DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...

Builds on positive top-line data from first cohort demonstrating significant reduction in urinary incontinence episodes Paris, France, October 6, 2025 – EG 427, a biotechnology company leading the ...

PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP ...

Dr. Graham Erwin, assistant professor of molecular and human genetics at Baylor College of Medicine, has been awarded the National Institutes of ...

When Matt Hill, PhD, was in graduate school, the human genome sequence was more or less finished and companies like 454 and Solexa were starting to make waves in next-gen sequencing (NGS). But Hill ...

Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at 12 weeksGood tolerability with no systemic side effectsFirst ...